About 

Universe Pharmaceuticals Stock (NASDAQ: UPC)

Universe Pharmaceuticals Stock (NASDAQ:UPC), Trade Ideas

Universe Pharmaceuticals

Universe Pharmaceuticals Inc is a pharmaceutical company specializing in the manufacturing, marketing, sales and distribution of traditional Chinese medicine derivatives products targeting the elderly with the goal of addressing their physical conditions in the ageing process and promoting their general well-being. The company also sells biomedical drugs, medical instruments, Traditional Chinese Medicine Pieces, and dietary supplements manufactured by third-party pharmaceutical companies. Its products are under two categories namely treatment and relief for common chronic health conditions in the elderly designed to achieve physical wellness and longevity (Chronic Condition Treatments), and cold and flu medications.

News

Penny Stocks

Small Cap

Intraday Update

Markets

Movers

Trading Ideas

AGRI

ANTE

BFRI

BTCY

BTTX

CISO

CURO

EVLV

GXAI

MicroCloud Hologram Inc. - Ordinary Shares

HOLO

INMD

IOVA

LICN

LUNR

LXRX

MEDS

MNPR

OCGN

OPEN

QBTS

QRTEA

RAPT

SIEN

SISI

SMCI

SMMT

SPRC

SSRM

TANH

TIRX

TNYA

TVGN

VZIO

Shares of  Fluor Corporation (NYSE: FLR) fell during Tuesday’s session following fourth-quarter results.

Why Fluor Shares Are Trading Lower By Around 8%? Here Are Other Stocks Moving In Tuesday&#39;s Mid-Day Session

Pre-Market Outlook

AGMH

TCTM

QBST

Shares of  Discover Financial Services (NYSE: DFS) shares rose sharply in today’s pre-market trading.

Why Discover Financial Services Shares Are Trading Higher By Around 11%; Here Are 20 Stocks Moving Premarket

AMAM

AMPE

ARBK

ARDX

AREN

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXNX

BCRX

BFLY

BNZI

BSGM

CROX

CYCC

DADA

DVAX

ELEV

FSLY

HARP

LMDX

NEXI

NKTX

PACB

PRAX

PRTA

RGNX

RVNC

RXST

SHPH

SILK

SNMP

SPEC

STSS

STTK

TCJH

TREE

UPWK

VERO

VINC

ZJYL

Shares of  RxSight, Inc. (NASDAQ: RXST) rose sharply during Monday’s session after the company issued preliminary FY23 and FY24 revenue guidance above estimates.

Also, Needham maintained a Buy rating on the stock and raised its price target from $35 to $41.

Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday&#39;s Mid-Day Session

Universe Pharmaceuticals Inc - Ordinary Shares

Universe Pharmaceuticals Inc

UNI-PRESIDENT C/H UNS/ADR by Uni-President China Holdings Ltd.

Uni-President China Holdings Ltd

UNIVERSAL POTASH CORP by Universal Potash Corp.

Universal Potash Corp

Needham analyst John Todaro reiterates CompoSecure (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CMPO#NASDAQ">CMPO</a>) with a Buy and maintains $15 price target.

Price Target

Reiteration

Analyst Ratings

CMPO

Needham Reiterates Buy on CompoSecure, Maintains $15 Price Target

Guidance

HGTY

Hagerty Reaffirmed 2024 Outlook For 15%-17% Total Revenue Growth, 116%-148% Net Income Growth And 41-53% Adjusted EBITDA Growth

WIIM

CMND

Clearmind Medicine shares are trading higher after the company signed an exclusive patent licensing agreement with Yissum Research Development Company.

Reiterating Full-Year 2024 Guidance
Karen Williams, Amex GBT's Chief Financial Officer, stated: "First quarter performance was in line with our expectations, and we remain confident in delivering the strong profitability growth we have guided to for the full year. We expect our continued focus on productivity, margin expansion and cash flow acceleration will drive full-year Adjusted EBITDA growth between 18% and 32% and Free Cash Flow generation in excess of $100 million in 2024."
The guidance below does not incorporate the impact of the CWT acquisition, which is expected to close in the second half of 2024.
<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="1" rowspan="1">&nbsp;</td>
<td colspan="1" rowspan="1">Full-Year 2024 Guidance</td>
<td colspan="1" rowspan="1">Year-over-Year Growth</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Revenue</td>
<td colspan="1" rowspan="1">$2.43B – $2.50B</td>
<td colspan="1" rowspan="1">+ 6% – 9%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA</td>
<td colspan="1" rowspan="1">$450M – $500M</td>
<td colspan="1" rowspan="1">+ 18% – 32%</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Adjusted EBITDA Margin</td>
<td colspan="1" rowspan="1">18% – 20%</td>
<td colspan="1" rowspan="1">+ ~150bps – 350bps</td>
</tr>
<tr>
<td colspan="1" rowspan="1">Free Cash Flow</td>
<td colspan="1" rowspan="1">&gt; $100M</td>
<td colspan="1" rowspan="1">&nbsp;</td>
</tr>
</tbody>
</table>
</figure>
Please refer to the section below titled "Reconciliation of Full-Year 2024 Adjusted EBITDA and Free Cash Flow Guidance" for a description of certain assumptions and risks associated with this guidance and reconciliation to GAAP.

GBTG

Global Business Travel Group Reiterates FY24 Revenue Guidance Of $2.43B-$2.5B Vs 2.48B Est.

Raymond James analyst Brian Gesuale initiates coverage on UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Outperform rating and announces Price Target of $42.

Initiation

Raymond James Initiates Coverage On UL Solutions with Outperform Rating, Announces Price Target of $42

During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have high free cash flows and reward shareholders with a <a href="https://www.benzinga.com/yield-investments">high dividend payout</a>. 
Benzinga readers can review the latest analyst takes on their favorite stocks by visiting our <a href="https://www.benzinga.com/analyst-stock-ratings">Analyst Stock Ratings</a> page. Traders can sort through Benzinga's extensive database of analyst ratings, including <a href="https://www.benzinga.com/analyst-ratings/analyst-color/22/09/28888638/exclusive-study-finds-benzinga-analyst-ratings-data-yields-market-beating-strategie">by analyst accuracy</a>.
Below are the ratings of the most accurate analysts for three high-yielding stocks in the consumer staples sector.
<h3 class="wp-block-heading">Cal-Maine Foods, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CALM#NASDAQ">CALM</a>)</h3>
<ul>
<li>Dividend Yield: 3.30%</li>
<li>Stephens &amp; Co. analyst Ben Beinvenu reiterated an Equal-Weight rating with a price target of $65 on April 3, 2024. This analyst has an accuracy rate of 75%.</li>
<li>Goldman Sachs analyst Adam Samuelson maintained a Sell rating and increased the price target from $42 to $47 on March 12, 2024. This analyst has an accuracy rate of 66%.</li>
<li>Recent News: On April 4, Cal-Maine Foods said Jeff Hardin, Senior Vice President of Sales, is retiring from his position with the Company, effective July 23, 2024.</li>
</ul>
<h3 class="wp-block-heading">Altria Group, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MO#NYSE">MO</a>)</h3>
<ul>
<li>Dividend Yield: 9.01%</li>
<li>Stifel analyst Matthew Smithreiterated a Buy rating with a price target of $50 on March 25. This analyst has an accuracy rate of 64%.</li>
<li>Morgan Stanley analyst Pamela Kaufman reiterated an Equal-Weight rating with a price target of $45 on July 18, 2023. This analyst has an accuracy rate of 68%.</li>
<li>Recent News: On April 25, Altria Group reported a first-quarter FY24 sales decline of 2.5% year-on-year to $5.58 billion, beating the analyst consensus estimate of $4.71 billion.</li>
</ul>
<h3 class="wp-block-heading">Walgreens Boots Alliance, Inc. &nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/WBA#NASDAQ">WBA</a>)</h3>
<ul>
<li>Dividend Yield: 5.79%</li>
<li>UBS analyst Kevin Caliendomaintained a Neutral rating and cut the price target from $25 to $22 on April 3. This analyst has an accuracy rate of 74%.</li>
<li>Morgan Stanley analyst Erin Wright maintained an Underweight rating and lowered the price target from $21 to $20 on April 1. This analyst has an accuracy rate of 73%.</li>
<li>Recent News: On April 24, DoorDash and Walgreens announced a new collaboration to offer SNAP/EBT payment at nearly 7,800 Walgreens stores across the country.</li>
</ul>
Read More: <a href="https://www.benzinga.com/trading-ideas/long-ideas/24/05/38663466/over-10m-bet-on-sensata-technologies-check-out-these-4-stocks-insiders-are-buying">Over $10M Bet On Sensata Technologies? Check Out These 4 Stocks Insiders Are Buying</a>

Dividends

CALM

Wall Street's Most Accurate Analysts' Views On 3 Risk Off Stocks With Over 3% Dividend Yields

Biotech

General

UPDATE:  Agreement Provides Clearmind With Exclusive Global Rights To Further Develop, Manufacture, And Commercialize Innovative Compounds Invented By Professors Rami Yaka, Ahmed Masaewa And Avi Priel From The Hebrew University

Global Business Travel (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GBTG#NYSE">GBTG</a>) reported quarterly losses of $(0.04) per share which missed the analyst consensus estimate of $0.04 by 200 percent. This is a 33.33 percent increase over losses of $(0.06) per share from the same period last year. The company reported quarterly sales of $610.00 million which missed the analyst consensus estimate of $624.28 million by 2.29 percent. This is a 5.54 percent increase over sales of $578.00 million the same period last year.

Earnings

Global Business Travel Q1 EPS $(0.04) Misses $0.04 Estimate, Sales $610.00M Miss $624.28M Estimate

Rockwell Automation shares are trading lower after the company reported Q2 financial results and cut its FY24 adjusted EPS guidance.

Needham analyst Joshua Reilly reiterates Axon Enterprise (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AXON#NASDAQ">AXON</a>) with a Buy and maintains $400 price target.

AXON

Needham Reiterates Buy on Axon Enterprise, Maintains $400 Price Target

Piper Sandler analyst Michael Lavery maintains Tyson Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TSN#NYSE">TSN</a>) with a Neutral and raises the price target from $55 to $57.

Piper Sandler Maintains Neutral on Tyson Foods, Raises Price Target to $57

Clearmind Medicine Signs Exclusive Patent Licensing Agreement With Yissum Research Development Company; Under Agreement, Clearmind Receives Exclusive Rights To Develop, Manufacture, And Commercialize Novel Compounds For Treating PTSD And Other Mental Health Disorders

ELDN

Eledon Pharmaceuticals shares are trading lower after the company announced an $50 million oversubscribed private placement. The company announced clinical progress with tegoprubart in the prevention of transplant rejection.

The Company affirmed its net sales and Adjusted EBITDA financial&nbsp;outlook&nbsp;for 2024, which was previously provided in March. The Company continues to expect slight increases in both net sales and Adjusted EBITDA for the full year, with declines in the first half of the year offset by growth in the second half.
The Company has adjusted its Free Cash Flow&nbsp;outlook&nbsp;to be approximately half of the 2023 level, which compares to the previous&nbsp;outlook&nbsp;of&nbsp;$5 million&nbsp;to&nbsp;$10 million&nbsp;below prior year. The change compared to the prior&nbsp;outlook&nbsp;primarily reflects the near-term impact of the newly signed contract with one of the Company&#39;s larger customers, which should benefit cash flow through 2029, but negatively impact Free Cash Flow in 2024 due to up-front incentives. Compared to prior year, the Free Cash Flow&nbsp;outlook&nbsp;also reflects increased capital spending investment, including investment in a new state-of-the-art secure card production facility in Indiana. The Company generated&nbsp;$27.6 million&nbsp;of Free Cash Flow in 2023.
The Company continues to expect its year-end 2024 Net Leverage Ratio to be between 3.0x and 3.5x.

PMTS

CPI Card Expects Slight Increases In Both Net Sales And Adjusted EBITDA For Full Year, With Declines In The First Half Of The Year Offset By Growth In Second Half

HC Wainwright &amp; Co. analyst Andrew Fein reiterates Vertex Pharmaceuticals (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/VRTX#NASDAQ">VRTX</a>) with a Buy and maintains $462 price target.

VRTX

HC Wainwright & Co. Reiterates Buy on Vertex Pharmaceuticals, Maintains $462 Price Target

Oppenheimer analyst Brian Schwartz maintains Zeta Global Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ZETA#NYSE">ZETA</a>) with a Outperform and raises the price target from $14 to $18.

ZETA

Oppenheimer Maintains Outperform on Zeta Global Holdings, Raises Price Target to $18

Innovid anticipates continued revenue growth and margin expansion in 2024.&nbsp;FY 2024 Adjusted EBITDA&nbsp;in a range between&nbsp;$24 million&nbsp;and&nbsp;$29 million, raised from the prior range of&nbsp;$22 million&nbsp;and&nbsp;$28 million.

Innovid Expects Q2 Revenue Of $37.5M-$39.5M (Est $38.3M), Raises FY24 Outlook From $154M-$162M To $156M-$163M (Est $158.294M)

REFI

Chicago Atlantic Real Estate Finance Affirmed 2024 Outlook Issued On Mar. 12

In a significant development in the Chinese electric vehicle (EV) market, Nio (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NIO#NYSE">NIO</a>) has teamed up with BYD (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDF#OTC">BYDDF</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/BYDDY#OTC">BYDDY</a>) to procure batteries for a new, competitively-priced EV brand.
What Happened: This partnership marks a major milestone for BYD, which has been striving to expand its revenue streams beyond its own EV sales, Reuters reported on Tuesday. The collaboration also highlights the fierce competition in China&#8217;s EV market, especially in relation to pricing and battery costs, the most significant expense in a new vehicle.
Nio, which initially planned to produce batteries internally, has now shifted its strategy towards cost reduction to offset losses. The company announced on Monday that the new brand would be called &#8220;Onvo&#8221; and is intended to compete with Elon Musk&#8216;s Tesla Model Y.
See Also: <a href="https://www.benzinga.com/general/social-media/24/05/38649736/tesla-semi-with-walmart-branding-spotted-whats-next-for-ev-giants-push-into-semi-trucks?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">Tesla Semi With Walmart Branding Spotted: What&#8217;s Next For EV Giant&#8217;s Push Into Semi-Trucks?</a>
Currently, Nio sources most of its batteries from industry leader CATL. Under the new agreement, BYD will join CATL in supplying a smaller battery pack for one version of the new Onvo EV. Another Chinese battery maker, CALB, will provide a larger battery pack of 85 kilowatt hours.
Why It Matters: This development comes amidst a major shift in China&#8217;s EV market. In March, Warren Buffett-backed BYD <a href="https://www.benzinga.com/markets/asia/24/03/37776137/chinas-ev-market-charges-forward-warren-buffett-backed-byd-predicts-50-nev-penetration-as-top-player">predicted a significant change</a> in the new energy vehicle (NEV) landscape. This bullish outlook was shared at the China EV 100 Forum in Beijing, where key players outlined their strategies for the rapidly evolving market.
Earlier in the same month, BYD and Xiaomi <a href="https://www.benzinga.com/news/24/03/37616662/teslas-chinese-rivals-are-coming-for-the-throat-byd-xiaomi-sharpen-knives-for-all-out-ev-price-war">initiated a race to make EVs </a>more affordable than their gasoline counterparts. BYD, which surpassed Tesla as the largest EV manufacturer globally in the fourth quarter of 2023, is now focusing on competing with internal combustion engine vehicles rather than other EV makers.
In 2008, Berkshire invested around $230 million in BYD, obtaining 225 million shares and a 20.49% stake in Class H shares. Over time,<a href="https://www.benzinga.com/news/24/02/36904335/warren-buffett-backed-byd-reports-impressive-33-1-yoy-growth-in-january-sales-continues-to-scale-sal" target="_blank" rel="noreferrer noopener">&nbsp;it has reduced its stake</a>&nbsp;and now holds approximately 87.6 million BYD H Shares, equivalent to a 7.98% stake.
Price Action: On Monday, BYDDF shares closed at $29.05&nbsp;and BYDDY shares closed at $57.93, while Nio&#8217;s shares closed at $5.69 on the same day, with a slight decrease to 5.58 USD on May 7, 2024.
Read Next: <a href="https://www.benzinga.com/news/24/05/38606510/us-is-currently-sc-ed-ex-cruise-ceo-calls-for-manufacturing-makeover-to-win-over-chinese-auto-rivals?itm_source=parsely-api" target="_blank" rel="noreferrer noopener">&#8216;US Is Currently Sc&#x2A;&#x2A;&#x2A;ed:&#8217; Ex-Cruise CEO Calls For Manufacturing Makeover To Win Over Chinese Auto Rivals</a>
Image via Shutterstock
<div style="font-family: 'Lato', sans-serif">
<div>
<hr style="border: 0;height: 5px;background: #225aa9" />
<div style="background-color: #f5f5f5;background-position: center;background-size: cover;justify-content: center"></div>

 Engineered by Benzinga Neuro, Edited by 
 <a href="https://www.benzinga.com/topic/Pooja-Rajkumari" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Pooja Rajkumari</a> 
 
 
<hr style="border: 0;height: 1px;background: #225aa9" />

 The GPT-4-based Benzinga Neuro content generation system exploits the extensive Benzinga Ecosystem, including native data, APIs, and more to create comprehensive and timely stories for you. 
 <a href="https://www.benzinga.com/author/benzinga-neuro" target="_blank" rel="noopener" style="color: #225aa9;text-decoration: none">Learn more.</a>
 
<hr style="border: 0;height: 5px;background: #225aa9" />
 </div>
</div>

Tech

BYDDF

BYDDY

Tesla's Chinese Rival Nio Partners With Warren Buffett-Backed BYD To Launch Budget-Friendly EV Brand

SOPH

SOPHiA GENETICS Reaffirms FY24 Revenue $78M-$81M Vs $79.168M Est.

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Gaxos.AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gxai-stock-quote/">GXAI</a>) stock is sliding lower on Tuesday after the non-fungible tokens (NFT) game development and management company&rsquo;s shares <a href="https://www.nasdaq.com/press-release/gaxos-gaming-to-launch-ai-solution-for-game-developers-and-studios-2024-02-16">saw a major rally on Friday</a>.



Shares of GXAI stock closed out Friday up 172.9%. That came alongside roughly 108 million shares of Gaxos.AI stock changing hands. To put that in perspective, the company&rsquo;s daily average trading volume is well below that at about 2.2 million shares.



All of this attention was placed on Gaxos.AI after the company filed announced plans for using artificial intelligence (<a href="https://investorplace.com/stock-quotes/ai-stock-quote/">AI</a>) in game development. The company notes that this will focus on &ldquo;dynamic content generation, seamless integration, and personalized solutions.&rdquo;



Vadim Mats, CEO of Gaxos.AI, said the following about this plan.




&ldquo;With the technological success of implementing AI into our games, we are excited to bring this AI service to market. By embracing this tech, the game development community can unlock new levels of creativity, efficiency, and player interaction. This is a big step in our gaming strategy as we look forward to delivering value to shareholders.&rdquo;




<h2>GXAI Stock Movement Today</h2>



Shares of GXAI stock are retreating on Tuesday after that Friday rally. However, the shares are giving up all of the ground that they gained. Instead, the stock is down 20.9% as of this writing with roughly 1.4 million units traded.



Investors who want more of the most recent stock market news are in the right place!



InvestorPlace is home to all of the hottest stock market stories for Tuesday! That includes everything happening with Universe Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/upc-stock-quote/">UPC</a>) stock, Trxade Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/meds-stock-quote/">MEDS</a>)&nbsp;stock and AgriForce Growing&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/agri-stock-quote/">AGRI</a>) stock this morning. You can learn all about these matters at the following links!



<h2>More Stock Market News for Tuesday</h2>



<ul><li><a href="https://investorplace.com/2024/02/why-is-universe-pharmaceuticals-upc-stock-down-29-today/">Why Is Universe Pharmaceuticals (UPC) Stock Down 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/02/why-is-trxade-health-meds-stock-up-230-today/">Why Is Trxade Health (MEDS) Stock Up 230% Today?</a></li>



<li><a href="https://investorplace.com/2024/02/why-is-agriforce-growing-agri-stock-up-218-today/">Why Is AgriForce Growing (AGRI) Stock Up 218% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.



With only the rarest exceptions,&nbsp;InvestorPlace&nbsp;does not publish commentary about companies that have a market cap of less than $100 million or trade less than 100,000 shares each day. That&rsquo;s because these &ldquo;<a href="https://investorplace.com/stock-types/penny-stocks/">penny stocks</a>&rdquo; are frequently the playground for scam artists and market manipulators. If we ever do publish commentary on a low-volume stock that may be affected by our commentary, we demand that&#8239;&nbsp;<a href="http://investorplace.com/" target="_blank">InvestorPlace.com</a>&rsquo;s&nbsp;writers disclose this fact and warn readers of the risks.&nbsp;



Read More:&#8239;Penny Stocks &mdash;&nbsp;<a href="https://investorplace.com/2014/05/fraud-penny-stocks-scams/" target="_blank">How to Profit Without Getting Scammed</a>
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/10/no-1-ai-investment-might-be-this-company-youve-never-heard-of/?cid=MKT764787&amp;eid=MKT771245">The #1 AI Investment Might Be This Company You&rsquo;ve Never Heard Of</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT771236">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/why-is-gaxos-ai-gxai-stock-down-21-today/">Why Is Gaxos.AI (GXAI) Stock Down 21% Today?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

Why Is Gaxos.AI (GXAI) Stock Down 21% Today?

<a href="https://investorplace.com">InvestorPlace - Stock Market News, Stock Advice &amp; Trading Tips</a>
Super Micro Computer (NASDAQ:<a href="https://investorplace.com/stock-quotes/smci-stock-quote/">SMCI</a>) stock is a hot topic on Tuesday after getting a new price prediction from Rosenblatt&nbsp;analyst Hans Mosesmann.



The Rosenblatt&nbsp;analyst increased his price target for SMCI shares from $700 to $1,300. That&rsquo;s a potential 61.8% upside compared to its prior closing price. It&rsquo;s also the highest Wall Street price prediction with the analysts&rsquo; consensus sitting at $629.20 per share.



Mosesmann continues to hold a bull stance on SMCI stock with a &ldquo;buy&rdquo; rating for the shares. For the record, the analysts&rsquo; consensus rating for SMCI shares is moderate buy based on 10 opinions.



<h2>Why The Bull Stance on SMCI Stock?</h2>



Here&rsquo;s what the Rosenblatt&nbsp;analyst said about Super Micro Computer in a note to clients obtained by CNBC.




&ldquo;Our increased price target for SMCI &hellip; is a reflection of the robust growth in AI computing and the company&rsquo;s strategic position within this rapidly evolving market. Moreover, Supermicro&rsquo;s success in gaining market share in a relatively static market for general-purpose Xeon processors, thanks to its U.S.-centric manufacturing approach, signals a readiness to tackle and adapt to the dynamic demands in AI, including liquid cooling and comprehensive product offerings.&rdquo;




SMCI stock is up 2.1% as of Tuesday morning with some 764,000 shares traded. It&rsquo;s daily average trading volume is about 7.5 million shares.



Investors can find all of the hottest stock market news ready to go down below!



We are offering all of the latest stock market stories traders need to know about on Tuesday! Among that is what&rsquo;s going on with shares of Gaxos.AI&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/gxai-stock-quote/">GXAI</a>), Universe Pharmaceuticals&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/upc-stock-quote/">UPC</a>) and Trxade Health&nbsp;(NASDAQ:<a href="https://investorplace.com/stock-quotes/meds-stock-quote/">MEDS</a>) stock this morning. All of that info is available at the following links!



<h2>More Tuesday Stock Market News</h2>



<ul><li><a href="https://investorplace.com/2024/02/why-is-gaxos-ai-gxai-stock-down-21-today/">Why Is Gaxos.AI (GXAI) Stock Down 21% Today?</a></li>



<li><a href="https://investorplace.com/2024/02/why-is-universe-pharmaceuticals-upc-stock-down-29-today/">Why Is Universe Pharmaceuticals (UPC) Stock Down 29% Today?</a></li>



<li><a href="https://investorplace.com/2024/02/why-is-trxade-health-meds-stock-up-230-today/">Why Is Trxade Health (MEDS) Stock Up 230% Today?</a></li>
</ul>On the date of publication, William White&nbsp;did not have (either directly or indirectly) any positions in the securities mentioned in this article.&nbsp;The opinions expressed in this article are those of the writer, subject to the InvestorPlace.com&nbsp;<a href="https://investorplace.com/corporate/investorplace-publishing-guidelines/" target="_blank">Publishing Guidelines</a>.
<h3>More From InvestorPlace</h3>
		<ul><li>
						<a href="https://investorplace.com/2023/07/venture-capitalist-predicts-this-chatgpt-announcement-will-shock-the-world/?cid=MKT744191&amp;eid=MKT766413">ChatGPT IPO Could Shock the World, Make This Move Before the Announcement</a>
					</li>
																<li>
						<a href="https://investorplace.com/2023/07/elon-musks-project-omega-stuns-silicon-valley-insiders/?cid=MKT738510&amp;eid=MKT766411">Musk&rsquo;s &ldquo;Project Omega&rdquo; May Be Set to Mint New Millionaires. Here&rsquo;s How to Get In.</a>
					</li>
									</ul><div>
			<div></div>
						<div></div>
					</div>
	The post <a href="https://investorplace.com/2024/02/smci-stock-price-prediction-can-super-micro-computer-rally-60-more-from-here/">SMCI Stock Price Prediction: Can Super Micro Computer Rally 60% More From Here?</a> appeared first on <a href="https://investorplace.com">InvestorPlace</a>.

SMCI Stock Price Prediction: Can Super Micro Computer Rally 60% More From Here?

Nano X Imaging, Annexon among healthcare movers

Nano-X Imaging, Annexon among healthcare movers

GCT, VHC and IPWR among mid-day movers

These Healthcare stocks are trading higher:-Iovance Biotherapeutics Inc (IOVA) stock is trading at $12.08, a gain of $2.93, or 31.75%, on high volume.  Iovance Biotherapeutics Inc. gets a Sentiment Score of Very Bearish from InvestorsObserver and receives an average analyst recommendation of Strong Buy with a price target

Healthcare Stocks Moving Tuesday: IOVA, GRYP, OCGN, ICU, RAPT, SMMT, UPC, NNOX

iBio, Mesoblast, Kodiak Sciences among healthcare movers

BRNS, UPC and KWE among mid-day movers

Palisade Bio, Marinus Pharmaceuticals, Poseida Therapeutics among healthcare movers